therapeutic combinations (a B2B model). We attack bacteria with their "own medicine": using compounds of beneficial bacteria from healthy tissue's microbiota, synergistically combined with biopolymers and antibiotics. We have already conducted in vivo studies, proving our solution's safety and improving the efficacy of a commercial antibiotic from 30% to 85% with our co-formulation. We are bringing to market over 15 years of R&D experience in anti-biofilm solutions in high antimicrobial resistance environments, combined with a biopharma business strategy background. Our MVP is focused on Gram-positive infections (prosthetic joint and respiratory models). We strongly believe that: where antibiotics fail, our solution begins.